International partnership to advance the development of a new vaccine against Shigella and ETEC

Horizon2020 award to consortium will support the testing of an innovative live attenuated vaccine in phase I clinical trials in Europe and Bangladesh.

Under coordination by EVI, the SHIGETECVAX consortium, made up of partners including EVI, Eveliqure, icddr,b, University of Gothenburg, and PATH, will be advancing a radically new approach for a vaccine against Shigella and ETEC, developed by Eveliqure Biotechnologies.

To read the full EVI news release, please click this link:

http://www.euvaccine.eu/sites/default/files/uploads/Files/SHIGETECVAX_news%20relsease-EVI_FINAL_190910.pdf

To read the full EVQ news release, please click this link:

https://dd0878df-7f1d-4cd4-99b5-1a0d62bc3ecf.filesusr.com/ugd/e91f01_e2439e5923ab4779bb015763e62210d3.pdf